-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price Target

Benzinga·07/13/2026 11:06:21
語音播報
JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announces $12 price target.